Good afternoon :)
Switch to
Place Order

Ajooni Biotech Ltd

AJOONI
Health CarePharmaceuticals
SmallcapWith a market cap of ₹58 cr, stock is ranked 2,290
High RiskStock is 3.16x as volatile as Nifty
58.152.10 (-3.49%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹58 cr, stock is ranked 2,290
High RiskStock is 3.16x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
157.25
PB RatioPB Ratio
3.72
Dividend YieldDiv. Yield
Sector PESector PE
38.74
Sector PBSector PB
5.18
Sector Div YldSctr Div Yld
0.66%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Ajooni Biotech Pvt Ltd is a manufacturer of medicinals and botanicals

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

201820192020202142.5940.0640.0951.060.390.410.330.37
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Reply to Clarification- Financial results 
Announced OnNov 26, 2021

The Exchange had sought clarification from Ajooni Biotech Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Statement of Cash Flow not submitted The response of the Company is enclosed. | Download

The Exchange had sought clarification from Ajooni Biotech Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Statement of Cash Flow not submitted The response of the Company is enclosed. | Download

Financial Result Updates 
Announced OnNov 13, 2021

Ajooni Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2021. | Download

Ajooni Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2021. | Download

Outcome of Board Meeting 
Announced OnNov 13, 2021

Ajooni Biotech Limited has informed the Exchange regarding Board meeting held on November 13, 2021. | Download

Ajooni Biotech Limited has informed the Exchange regarding Board meeting held on November 13, 2021. | Download

See all events